SSA
PHAT icon

Schonfeld Strategic Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Sell
15,614
-15,330
-50% -$194K ﹤0.01% 1776
2025
Q4 		$513K Buy
+30,944
New +$442K ﹤0.01% 1388
2025
Q3 		– Sell
-306,399
Closed -$2.94M – 2494
2025
Q2 		$2.94M Buy
+306,399
New +$1.7M 0.02% 794
2024
Q4 		– Sell
-208,640
Closed -$3.77M – 2299
2024
Q3 		$3.77M Buy
208,640
+40,317
+24% +$563K 0.03% 634
2024
Q2 		$1.73M Buy
168,323
+23,623
+16% +$243K 0.01% 967
2024
Q1 		$1.54M Buy
144,700
+83,700
+137% +$711K 0.01% 1075
2023
Q4 		$557K Buy
61,000
+22,256
+57% +$192K ﹤0.01% 1248
2023
Q3 		$402K Buy
+38,744
New +$531K ﹤0.01% 1259

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return